Small BusinessDaiichi moves SC against SAT
Leading Japanese drug maker Daiichi Sankyo has challenged the Securities Appellate Tribunal (SAT) judgement that asked it to make an open offer to shareholders of Zenotech Labs at Rs 160 per share.
- India Eco Summit: Daiichi to launch Ranbaxy"s drugs in Japan - Shankar Sharma gets four-week breather - Shankar Sharma given 4-weeks time to appeal in SC - Not the right medicine - Daiichi Sankyo, JK Tyre & Financial Tech Q2 result - Daiichi Sankyo net income drops 45% in Apr-Sept
Daiichi Sankyo is to make an open offer to Zenotech’s shareholders to acquire 20 per cent additional stake in the Hyderabad-based firm.
A Bench headed by Justice S H Kapadia while posting the matter for final hearing on December 2 asked the parties to maintain status quo after senior counsel Mukul Rohtagi, appearing for Daiichi, submitted that the company was willing to give an undertaking stating that it would pay differential amount with interest within two weeks in case it loses.
However, the Bench said the rate would be “fixed by this court at the time of final hearing and, at that time, in case the petitioner (Daiichi) loses, it will pay full differential amount with interest in terms of the undertaking”.
The court also issued notices to Zenotech MD Jayaram Chigurupati and other shareholder who had moved the tribunal against Sebi’s nod to Daiichi’s offer price of Rs 113 per share.